Archives of Physical Medicine and Rehabilitation
Volume 89, Issue 4 , Pages 692-699 , April 2008

Time Course Analysis of the Effects of Botulinum Toxin Type A on Elbow Spasticity Based on Biomechanic and Electromyographic Parameters

  • Hsin-Min Lee, PhD

      Affiliations

    • Department of Physical Therapy, I-Shou University, Kaohsiung, Taiwan, ROC
    • ,
  • Jia-Jin Jason Chen, PhD

      Affiliations

    • Institute of Biomedical Engineering, National Cheng Kung University, Taiwan, ROC
    • Corresponding Author InformationReprint requests to Jia-Jin Jason Chen, PhD, Institute of Biomedical Engineering, National Cheng Kung University, Tainan 701, Taiwan
    • ,
  • Yi-Ning Wu, PhD

      Affiliations

    • Institute of Biomedical Engineering, National Cheng Kung University, Taiwan, ROC
    • ,
  • Yu-Lin Wang, MD

      Affiliations

    • Chi-Mei Hospital, Tainan, Taiwan, ROC
    • ,
  • Sheng-Chih Huang, MS

      Affiliations

    • Institute of Biomedical Engineering, National Cheng Kung University, Taiwan, ROC
    • ,
  • Maria Piotrkiewicz, PhD

      Affiliations

    • Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Poland.

References 

  1. Bakheit AM, Maynard VA, Curnow J, Hudson N, Kodapala S. The relation between Ashworth scale scores and the excitability of the alpha motor neurones in patients with post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry. 2003;74:646–648
  2. Mauritz KH. Gait training in hemiplegia. Eur J Neurol. 2002;9:23–29
  3. Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dysfunction. Muscle Nerve Suppl. 1997;6:S21–S35
  4. Hurvitz EA, Conti GE, Brown SH. Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection. Arch Phys Med Rehabil. 2003;84:444–454
  5. Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP. Are we underestimating the clinical efficacy of botulinum toxin (type A)? (Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population). Clin Rehabil. 2002;16:654–660
  6. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol. 2002;249:76–84
  7. Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol. 2003;21:476–480
  8. van Kuijk AA, Geurts AC, Bevaart BJ, van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. J Rehabil Med. 2002;34:51–61
  9. Wang HC, Hsieh LF, Chi WC, Lou SM. Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil. 2002;81:272–278
  10. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43:S16–S24
  11. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002;18(6 Suppl):S119–S124
  12. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206–207
  13. Biering-Sorensen F, Nielsen JB, Klinge K. Spasticity-assessment: a review. Spinal Cord. 2006;44:708–722
  14. Gregson JM, Leathley M, Moore AP, Sharma AK, Smith TL, Watkins CL. Reliability of the Tone Assessment Scale and the modified Ashworth scale as clinical tools for assessing poststroke spasticity. Arch Phys Med Rehabil. 1999;80:1013–1016
  15. Haas BM, Bergstrom E, Jamous A, Bennie A. The inter rater reliability of the original and of the modified Ashworth scale for the assessment of spasticity in patients with spinal cord injury. Spinal Cord. 1996;34:560–564
  16. Johnson GR. Outcome measures of spasticity. Eur J Neurol. 2002;9:10–16
  17. Lance JW. Symposium synopsis. In:  Feldman RG,  Young RR,  Koella WP editor. Spasticity: disordered motor control. Chicago: Year Book Medical; 1980;p. 485–494
  18. Sheean G. The pathophysiology of spasticity. Eur J Neurol. 2002;9(Suppl 1):3–9
  19. Broberg C, Grimby G. Measurement of torque during passive and active ankle movements in patients with muscle hypertonia (A methodological study). Scand J Rehabil Med. 1983;9(Suppl):108–117
  20. Firoozbakhsh KK, Kunkel CF, Scremin AM, Moneim MS. Isokinetic dynamometric technique for spasticity assessment. Am J Phys Med Rehabil. 1993;72:379–385
  21. Lee HM, Huang YZ, Chen JJ, Hwang IS. Quantitative analysis of the velocity related pathophysiology of spasticity and rigidity in the elbow flexors. J Neurol Neurosurg Psychiatry. 2002;72:621–629
  22. On AY, Kirazli Y, Kismali B, Aksit R. Mechanisms of action of phenol block and botulinum toxin type A in relieving spasticity: electrophysiologic investigation and follow-up. Am J Phys Med Rehabil. 1999;78:344–349
  23. Kamper DG, Rymer WZ. Quantitative features of the stretch response of extrinsic finger muscles in hemiparetic stroke. Muscle Nerve. 2000;23:954–961
  24. Voerman GE, Gregoric M, Hermens HJ. Neurophysiological methods for the assessment of spasticity: the Hoffmann reflex, the tendon reflex, and the stretch reflex. Disabil Rehabil. 2005;27:33–68
  25. Lee HM, Chen JJ, Ju MS, Lin CC, Poon PP. Validation of portable muscle tone measurement device for quantifying velocity-dependent properties in elbow spasticity. J Electromyogr Kinesiol. 2004;14:577–589
  26. Chen JJ, Wu YN, Huang SC, Lee HM, Wang YL. The use of a portable muscle tone measurement device to measure the effects of botulinum toxin type A on elbow flexor spasticity. Arch Phys Med Rehabil. 2005;86:1655–1660
  27. Sawner KA, LaVigne MJ. Brunnstrom’s movement therapy in hemiplegia: a neurophysiological approach. 2nd ed.. Philadelphia: JB Lippincott; 1992;
  28. Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil. 1999;13:373–383
  29. Bakheit AM. Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry. 2004;75:665–666
  30. Simpson DM, Alexander DN, O’Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46:1306–1310
  31. Stampacchia G, Bradaschia E, Rossi B. Change of stretch reflex threshold in spasticity: effect of botulinum toxin injections. Arch Ital Biol. 2004;142:265–273
  32. Pauri F, Boffa L, Cassetta E, Pasqualetti P, Rossini PM. Botulinum toxin type-A treatment in spastic paraparesis: a neurophysiological study. J Neurol Sci. 2000;181:89–97
  33. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004;85:1063–1069
  34. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. [published erratum in: J Neurol Neurosurg Psychiatry 2001;70:821] J Neurol Neurosurg Psychiatry. 2000;69:217–221
  35. Friedman A, Diamond M, Johnston MV, Daffner C. Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. Am J Phys Med Rehabil. 2000;79:53–59
  36. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001;8:559–565
  37. Lagalla G, Danni M, Reiter F, Ceravolo MG, Provinciali L. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil. 2000;79:377–384
  38. Wang RY, Tsai MW, Chan RC. Effects of surface spinal cord stimulation on spasticity and quantitative assessment of muscle tone in hemiplegic patients. Am J Phys Med Rehabil. 1998;77:282–287
  39. Pisano F, Miscio G, Del Conte C, Pianca D, Candeloro E, Colombo R. Quantitative measures of spasticity in post-stroke patients. Clin Neurophysiol. 2000;111:1015–1022
  40. Peng Q, Shah P, Selles RW, Gaebler-Spira DJ, Zhang LQ. Measurement of ankle spasticity in children with cerebral palsy using a manual spasticity evaluator. Conf Proc IEEE Eng Med Biol Soc. 2004;7:4896–4899
  41. Ghika J, Wiegner AW, Fang JJ, Davies L, Young RR, Growdon JH. Portable system for quantifying motor abnormalities in Parkinson’s disease. IEEE Trans Biomed Eng. 1993;40:276–283
  42. Prochazka A, Bennett DJ, Stephens MJ, et al. Measurement of rigidity in Parkinson’s disease. Mov Disord. 1997;12:24–32
  43. Miscio G, Del Conte C, Pianca D, et al. Botulinum toxin in post-stroke patients: stiffness modifications and clinical implications. J Neurol. 2004;251:189–196
  44. Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil. 2005;27:176–184

 Supported in part by National Health Research Institute of Taiwan (contract no. NHRI-EX 95-9524E1) and National Science Council of the ROC (contract nos. NSC 92-2320-B-214-001, NSC 93-2320-B-214-004).

 No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated.

PII: S0003-9993(08)00011-7

doi: 10.1016/j.apmr.2007.08.166

Archives of Physical Medicine and Rehabilitation
Volume 89, Issue 4 , Pages 692-699 , April 2008

Article Tools

* Image Usage & Resolution